The balance between FOXP3+ and CD8+ T-cells is another clinically linked parameter, as low-FOXP3/ high-CD8+ ratios have been linked with positive survival effects across multiple cancer types including NSCLC [18–19]. Here, FOXP3 is linked to non-small cell lung carcinoma.